Previous Close | 1.0600 |
Open | 1.0800 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 1.0400 - 1.0800 |
52 Week Range | 0.8900 - 6.3000 |
Volume | |
Avg. Volume | 200,251 |
Market Cap | 59.016M |
Beta (5Y Monthly) | 1.84 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.4200 |
Earnings Date | Aug 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.14 |
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will share new preclinical data at three upcoming scientific meetings. “These preclinical results build upon the foundation of data we have shared to date and expand our confidence in the ability of epigenomic controllers to upregulate or downregulate th
Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio.